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Hepatitis C virus (HCV) is a blood-borne pathogen causing acute and chronic hepatitis. A significant number of people chronically
infected with HCV develop cirrhosis and/or liver cancer. The pathophysiologic mechanisms of hepatocyte damage associated with
chronic HCV infection are not fully understood yet, mainly due to the lack of an in vitro system able to recapitulate the stages of
infection in vivo. Several studies underline that HCV virus replication depends on redox-sensitive cellular pathways; in addition, it
is known that virus itself induces alterations of the cellular redox state. However, the exact interplay between HCV replication and
oxidative stress has not been elucidated. In particular, the role of reduced glutathione (GSH) in HCV replication and infection is
still not clear. We set up an in vitro system, based on low m.o.i. of Huh7.5 cell line with a HCV infectious clone (J6/JFH1), that
reproduced the acute and persistent phases of HCV infection up to 76 days of culture. We demonstrated that the acute phase of
HCV infection is characterized by the elevated levels of reactive oxygen species (ROS) associated in part with an increase of
NADPH-oxidase transcripts and activity and a depletion of GSH accompanied by high rates of viral replication and apoptotic
cell death. Conversely, the chronic phase is characterized by a reestablishment of reduced environment due to a decreased ROS
production and increased GSH content in infected cells that might concur to the establishment of viral persistence. Treatment
with the prooxidant auranofin of the persistently infected cultures induced the increase of viral RNA titer, suggesting that a
prooxidant state could favor the reactivation of HCV viral replication that in turn caused cell damage and death. Our results
suggest that targeting the redox-sensitive host-cells pathways essential for viral replication and/or persistence may represent a
promising option for contrasting HCV infection.
1. Introduction
Hepatitis C virus (HCV), an RNA virus belonging to the Fla-
viviridae family, represents a major worldwide concern caus-
ing about 400,000 deaths worldwide every year [1]. HCV
replication cycle takes place into the cytoplasmic compart-
ment of hepatocyte, and it causes acute or chronic hepatitis.
The persistent HCV infection is clinically characterized by
lifelong low-level virus production, and it is accompanied
by the development of chronic liver infection (in about 80%
of infected patients) that can evolve to steatosis, fibrosis, cir-
rhosis, and in a small percentage (about 20%) of chronically
infected patients it can develop to the end-stage hepatocellu-
lar carcinoma [2].
Although the exact molecular mechanisms underlying
the HCV-related liver injury are not fully understood, redox
alterations of hepatocytes have been extensively described in
several chronic liver diseases [3, 4]. Oxidative stress, an
imbalance between the reactive oxygen species (ROS) pro-
duction and their clearance by scavenging molecules, has
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been recognized as a leading factor in inducing hepatocyte
death, inflammation, and fibrogenesis, which are responsi-
ble for induction and perpetuation of liver damage [5]. Sev-
eral authors report a rise of ROS levels during HCV
infection [6–13], and various viral proteins are known to
induce and/or augment the ROS production, including
HCV core, E1, E2, nonstructural (NS) 3, NS4B, and NS5A
[11, 14–17]. Moreover, the simultaneous induction of several
ROS-producing pathways and enzymes, such as the endoplas-
mic reticulum (ER) oxidoreductases [15, 18] and NADPH
(nicotinamide adenine dinucleotide phosphate) oxidases
(NOXs) [15, 16, 19], also contributes to HCV-induced oxida-
tive stress. On the contrary, other studies report an increase
in the antioxidant defenses, such as superoxide dismutase
(SOD), peroxiredoxin (PRDX), glutathione S-transferase
(GST) enzyme activity, and GSH levels [14, 20–23]. Glutathi-
one is an important radical scavenger that directly and indi-
rectly neutralizes a variety of reactive molecules, such as
superoxide anions (O2
⋅−), hydroxyl radicals, and hydrogen
peroxide (H2O2) [24]. The ratio between reduced (GSH)
and oxidized (GSSG) form of GSH is considered an impor-
tant indicator of the antioxidant capacity of the cell.
Conflicting results are shown about the effect of HCV on
intracellular GSH metabolism [17, 19, 23, 25–27]. Indeed,
Roe and collaborators [27] report a significant raise of GSSG
in HCV-infected cells, while increased GSH concentration
has been demonstrated by de Mochel et al. [19] using the
same in vitro infection system. Interestingly, Abdalla et al.
[20] describe the different effects of two viral proteins on cell
antioxidant defenses. In fact, hepatocytes overexpressing
HCV core protein have reduced GSH levels and increased
the oxidation of thioredoxin (Trx), while the overexpression
of viral NS5A protein (known for its ability to cause oxida-
tive stress) [16] increases antioxidant enzymes (MnSOD
and catalase), heme oxygenase-1 (HO-1), and GSH content.
Finally, patients with chronic hepatitis C show a depletion of
GSH content, which increases after antioxidant treatment
[28]. However, different genotypes of HCV exhibit different
abilities to induce oxidative stress [29]. In fact, in patients
chronically infected with genotype 1a/b, a sharp decrease
of reduced GSH level has been observed with respect to the
other genotypes, suggesting the more serious disease associ-
ated with this genotype [29].
Interestingly, the de novo synthesis of GSH is controlled
by the transcription factor Nrf2 (NF-E2-related factor 2),
which regulates the expression of cytoprotective genes. Some
studies demonstrate that acute HCV infection is associated
with an early induction of proteins functioning in cellular
stress responses, including the Nrf2-mediated oxidative
stress response [23, 25]. On the other hand, HCV core
impairs the Nrf2/ARE signaling pathway by inducing the
translocation of sMaf proteins in the cytoplasm, where they
bind to NS3 as part of the replication complex. As a result,
Nrf2 is trapped in the cytoplasm and is unable to function
as transcription factor [26, 30].
On the basis of the conflicting results reported in the
literature about the relationship between redox balance and
HCV infection, the goal of this study was to clarify whether
the virus is able to condition the redox environment of
infected cells in order to induce acute infection or to establish
its persistence into the cells. For this reason, we set up an
in vitro system that mimics as closely as possible the acute
and chronic HCV infection.
Here, we demonstrate that during the acute phase of
infection HCV replicates with a high rate, thus inducing
intense apoptosis in infected cells; in this phase, a marked
oxidative stress was registered mainly due to NOX4 activity
and to a decrease of GSH and consequently of GSH/GSSG
ratio. Conversely, during the chronic phase of infection,
low level of bothHCVreplication and apoptosiswasobserved,
ROSproduction returned tobasal level,GSHcontentwas rees-
tablished, and the GSH/GSSG ratio shifted versus the reduced
form of GSH. Moreover, the treatment of HCV-chronically
infected cells with a prooxidant drug, auranofin, was able to
reactivate viral replication.
2. Materials and Methods
2.1. Cell Lines. Huh-7.5 human hepatoma cells were gener-
ously provided by Dr. Charles M. Rice [31]. Cells were
grown in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma) supplemented with 100U/ml of penicil-
lin, 100μg/ml of streptomycin, nonessential amino acids,
and 10% fetal bovine serum (FBS) (Invitrogen) at 37°C in
5% CO2.
2.2. Virus. The virus stock used in this study was prepared
as described below. The FL-J6/JFH1-5’C19RLuc 2Ubi plas-
mid, encoding the entire viral genome of a chimeric strain
of HCV genotype 2a, J6/JFH1 [32], was kindly provided
by C. M. Rice. The plasmid was linearized by XbaI digestion
and treated with mung bean nuclease to remove 5′ end
overhangs. The linearized DNA templates were first purified
by phenol:chloroform extraction and ethanol precipitation
and then transcribed with T7 RNA polymerase using a
MEGAscript™ T7 kit (Ambion, Austin, TX) according to
the manufacturer’s protocol. For electroporation, Huh-7.5
cells were grown to 60–80% confluence, trypsinized, washed
twice in cold PBS, and resuspended in cold PBS at a concen-
tration of 2 × 107 cells/ml. 0.4ml aliquots were mixed with
10μg of in vitro transcribed RNA and dispensed into
0.4 cm Gene Pulser cuvettes (Bio-Rad). Samples were pulsed
using a Gene Pulser apparatus (Bio-Rad, Hercules, CA) with
a single pulse at 0.27 kV and 960mF. Cells were resus-
pended in 20ml of complete growth medium, plated and
incubated at 37°C, 5% CO2, and 100% relative humidity.
Cells were splitted every 3 days, and virus infectivity was
measured by immunofluorescence assay as described below
and expressed as TCDI50/ml. The culture supernatant from
the 4th passage was used to infect naïve Huh-7.5 cells at a
multiplicity of infection (m.o.i.) of 0.2 in serum-free
high-glucose DMEM. After 2 hours at 37°C, the medium
was removed and replaced with complete medium. After 7
days and 2 passages, the supernatants were collected, centri-
fuged at 1200 rpm for 10min at 4°C, cleared of debris
through filtration on 0.45μm pore size filters, and stored
at -80°C as virus stocks.
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2.3. Cell Infection and Viral Titer Assays. Huh7.5 cells were
plated, grown for 24 h, and then challenged with virus stock
in serum-free medium at 0.01 m.o.i. Culture supernatants
of uninfected cells served as a control (mock preparation).
Cells were incubated in the presence of the virus for 6 h
at 37°C. After the viral challenge, mock-infected and
virus-infected cells were washed with PBS and then cultured
with fresh medium containing 10% FBS.
The titer of infectious HCV was determined by the 50%
tissue culture infective dose (TCID50) assay. Cell superna-
tants were serially diluted 10-fold in complete DMEM and
used to infect 1× 104/well naïve Huh-7.5 cells in 96-well
plates (8 wells per dilution). The level of HCV infection
was determined three days postinfection by immunofluores-
cence staining for HCV core protein. The wells showing
positive staining for HCV core protein were counted, and
the TCID50 titer was interpolated using the Reed-Muench
method [33].
2.4. Cell Treatments. Auranofin was obtained from
Sigma-Aldrich (Heidelberg, Germany). The compound was
dissolved in dimethylsulfoxide (DMSO) and applied to the
cells at a final concentration of 200nM that is the concentra-
tion at which no toxic effects were observed. The highest
DMSO concentration present in the culture medium was
0.05%. Control cells were treated with an equivalent concen-
tration of vehicle.
2.5. Cytotoxicity Assay. Cytotoxicity of auranofin was deter-
mined by cell count, and cell viability was assessed by trypan
blue dye exclusion test.
2.6. Immunofluorescence Assay. Cells were fixed in methano-
l : acetone (50 : 50, V/V) for 20min at -20°C. After blocking
with PBS containing 1% bovine serum albumin (BSA) for
at least 30min, cells were incubated with mouse monoclonal
antihepatitis C virus core 1b antibody (Abcam, AB 58713);
bound antibodies were revealed with mouse anti-human
IgG conjugated with Alexa Fluor 488 (Life Technologies,
Z25102). After washing, the nuclei were stained with 1μg/ml
4,6-diamidino-2-phenylindole (DAPI; Molecular Probes) in
PBS for 15min at room temperature. Fluorescent images
were acquired on an Olympus IX70 microscope equipped
with Nanomover and softWoRx DeltaVision image acquisi-
tion software (Applied Precision, WA, USA) and a
U-PLAN-APO 40× objective. Images were captured under
constant exposure time, gain, and offset.
2.7. Western Blotting. Cells were detached, washed with cold
PBS, and centrifuged at 700 g for 10min. The pellet was lysed
in cold RIPA lysis buffer (20mM TRIS pH8, 150mM NaCl,
1% Triton-X 100, 0.1% SDS, 1% sodium deoxycholate) con-
taining protease and phosphatase inhibitors for 30min on
ice. Lysates were centrifuged at 10 000 g for 30min at 4°C to
remove debris.
Protein concentration of cell extracts was determined by
the Bradford method (Bio-Rad, 5000006). Lysates were
resolved by SDS-PAGE and blotted onto nitrocellulose mem-
branes. The membranes were blocked with 10% nonfat dry
milk in Tris-buffered saline containing 0.01% Tween-100
for 1 h at room temperature (RT) and then incubated with
specific primary antibodies used at final concentration of
1μg/ml. The antibodies used are as follows: rabbit poly-
clonal anti-NOX4 (Santa Cruz Biotechnology, sc-30141),
rabbit polyclonal anti-NOX1 (Abcam, ab55831), rabbit
monoclonal anti-Nrf2 (D1Z9C) (Cell Signaling Technology,
Euroclone, Pero (MI) Italy, 12721S), mouse monoclonal
antitubulin (Sigma-Aldrich, T5168), and mouse monoclonal
anti-Lamin A/C (Sigma-Aldrich, L1293). Immunocomplexes
were detected through peroxidase-coupled secondary anti-
bodies (Jackson), followed by enhanced chemiluminescence
(GE Healthcare Life Sciences). Densitometry was done using
Quantity One 1-D Analysis software (Bio-Rad).
2.8. Glutathione Assay. The measurement of total intracellu-
lar glutathione (tGSH) (including the reduced and oxidized
forms, GSH and GSSG, respectively) and GSSG was per-
formed by means of Cayman’s GSH assay kit (Cayman
Chemical Co., 703002) according to the manufacturer’s
instructions. Briefly, the confluent control and infected
Huh7.5 cells were washed twice with PBS, harvested using a
rubber policeman, and were homogenized by a freeze-thaw
method in 1ml of 50mM MES buffer pH6 containing
1mM EDTA. After centrifugation, a small amount of the
supernatant was used for the protein assay (Bio-Rad protein
assay). The residual supernatant was deproteinated by add-
ing an equal amount of 5%w/v of metaphosphoric acid. After
centrifugation (at 3000 ×g for 5min), the supernatant was
neutralized with 50μL of triethanolamine per ml of sample.
The tGSH level was then determined by the endpoint method
reading absorbance at 405nm after 25min, according to the
procedures recommended by the manufacturer. In another
experiment, GSH was masked by 2-vinylpyridine for 1 h
before the assay to determine the GSSG levels in the samples.
The tGSH and GSSG were determined by comparison with
standards, normalized to protein content, and expressed as
nmol/mg protein. The GSH content was obtained by sub-
tracting the GSSG from the tGSH.
2.9. Cell Death Determination. The quantitative evaluation
of apoptosis was performed by a double-staining flow
cytometry method using fluorescein isothiocyanate- (FITC-)
conjugated annexin V(AV)/propidium iodide (PI) apoptosis
detection kit (Marine Biological Laboratory, MBL, Woods
Hole, MA, USA), according to the manufacturer’s protocol,
which allows discrimination among early apoptotic, late
apoptotic, and necrotic cells.
2.10. ROS Assay. ROS production was determined by means
of the CellROX deep red reagent (Thermo Fisher, C10491),
which is a fluorogenic probe, as described in the manufac-
turer’s instructions. CellROX (5μM) was added to cell cul-
tures and incubated at 37°C for 30 minutes. Then cells
were fixed with paraformaldehyde (4%), and samples were
immediately analyzed with an LRS II cytometer (Becton
Dickinson, San Jose, CA, USA) equipped with a 488 argon
laser and a UVB laser. The data obtained were analyzed by
DIVA software (B&D). The median values of fluorescence
intensity histograms were used to provide a semiquantitative
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assessment of ROS production. Samples were acquired with
a FACScalibur cytometer (BD Biosciences) equipped with a
488 argon laser and with a 635 red diode laser. At least
20,000 events were acquired. Data were recorded and statis-
tically analyzed by a Macintosh computer using CellQuest
software (BD Biosciences). The median values of fluores-
cence intensity histograms were used to provide a semiquan-
titative assessment of ROS production.
2.11. Real-Time RT-PCR Analysis. Total RNA was isolated
from control and HCV-infected cells, harvested at the indi-
cated times p.i., with the RNeasy kit (Qiagen, 74104) accord-
ing to the manufacturer’s instructions. Isolated RNA (1μg)
was reverse transcribed to cDNA using iScript™ cDNA Syn-
thesis Kit (Bio-Rad, 1708890). A comparative real-time PCR
analysis of gene expression was performed with the iQ™
SYBR Green Supermix (Bio-Rad, 170-8880) and analyzed
on LightCycler iQ™ 5 (Bio-Rad). The following forward
and reverse primers were used: NOX4 (5′-CAGGAGAAC
CAGGAGATTGTTG-3′ forward; 5′-GAAGTTGAGGGCA
TTCACCAGATG-3′ reverse), GR (5′-TTCAGTTGGCATG
TCATC-3′ forward; 5′-CCGTGGATAATTTCTATGTGA-
3′ reverse), GS (5′-GTGCTACTGATTGCTCAA-3′ forward;
5′-ACATGGATCTTCCTGTCT-3′ reverse), GCL (5′-AAGT
CCCTCTTCTTTCCA-3′ forward; 5′-CCTTGAATATTGG
CACATTG reverse), and GAPDH (5′-TGCGACTTCAA
CAGCAACTC-3′ forward; 5′-ATGTAGGCCATGAGGT
CCAC-3′ reverse).
The housekeeping glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used for normalization. Relative quan-
titative evaluation was performed by the comparative ΔΔCt
method. The results are presented as fold increase relative
to control cells. Dissociation curves were generated to ensure
a single amplicon had been produced.
The production of intracellular viral RNA was assessed
by quantitative one-step RT-PCR carried out using an ABI
7000 Real-Time PCR System (Applied Biosystems). 5μl of
total RNA was mixed with 2x TaqMan One-Step RT-PCR
Master Mix (ABI) and 1μM forward (TCCCGGGAGAG
CCATAGT), 1μM reverse primers (CCCAGTCTTCCCGG
CAATT), and 200 nM probe (FAM- CACCGGTTCCG
CAGACC -TAMRA). In vitro transcribed genotype 2a
RNA was used as a standard to quantify the copy numbers
of viral RNA.
2.12. Data Analysis and Statistics. A statistical significance
was evaluated using GraphPad Prism™ (San Diego, CA,
USA) software version 6.0. All data reported were verified
in at least 3 independent experiments and are reported as
means ± standard deviation (SD). Test details of each exper-
iment are described in the figure legends. P values < 0.05
were considered significant.
3. Results
3.1. Generation of an In Vitro Model of Acute and Chronic
HCV Infection. In the attempt to set up an HCV infec-
tious cell culture system that mimics acute and chronic
HCV infection, human hepatocellular carcinoma cell line
(Huh7.5) was infected with HCV at low (0.01) m.o.i. to
allow a multiple-cycle replication, as described in Materials
and Methods, and cultured up to 76 days.
After viral adsorption, cell culture viability was moni-
tored at different time points, and viral replication was eval-
uated by both real-time RT-PCR and immunofluorescence
assay for HCV core protein.
The number of viral core positive cells was estimated
by immunofluorescence to evaluate the extension of
HCV-infected cells. During thefirst two passages (8 days post-
infection), about 80% of the cells were stained for HCV core
protein, thus indicating a high rate of HCV replication corre-
sponding to the “acute” phase of infection (Figure 1(a) left
side). On the contrary, in the late stage of infection (76 days
postinfection p.i.), here referred as the “chronic” phase, only
about 15% of the cells expressed the core protein
(Figure 1(a) right side). Similarly, the HCV RNA in
intracellular compartment reached the highest titer
(3 59 × 107 ± 1 3 × 106 copies/μg total RNA ∗∗∗P < 0 001
vs. p0) 8 days p.i., and it decreased after the recovery phase
of the cell culture and during the chronic phase
(2 09 × 106 ± 1 2 × 106/μg total RNA at 44 days p.i and 6 ×
105 ± 9 × 102 copies/μg total RNA at 76 days p.i.)
(Figure 1(b)) that is consistent with a persistently infected
cell culture. Furthermore, in correspondence with the max-
imum titer of HCV RNA, the number of HCV-infected cells
was significantly reduced compared to uninfected ones
(Figure 1(c)). In fact, trypan blue dye exclusion assay
showed a significant decrease of alive cells during the
so-called “crisis” phase that lasted about two weeks during
which the infected cultures were not splitted. Particularly,
on days 8 and 14 most of the cells became rounded,
detached from the plate, and floated in the culture medium
(data not shown). Furthermore, FACS analysis of annexin
V/PI double staining of cells showed that infected cells
underwent apoptotic death only during the crisis phase. In
fact, as shown in Figure 1(d) (right panel), the percentage
of double-stained PI+/AV+ cells increased with respect to
uninfected cells (CTR) at passage 2 (p2). The 5-fold increase
in percentage of apoptotic cells (obtained as mean from 4
independent experiments) was detected in infected cultures
at 14 days p.i., compared to the uninfected ones
(Figure 1(d), right panel). Interestingly, apoptotic death in
infected cell cultures coincided with the highest intracellular
viral RNA titer (Figure 1(b)), thus suggesting a causative link
between the rate of HCV replication and cell death. Subse-
quently to the crisis phase, cells started a recovery phase at
the end of which the number of live cells, inHCV-infected cul-
tures, was comparable to that of control cells (Figure 1(c); see
value at p4). Accordingly, FACS analysis demonstrated that
from 37 days p.i. up to 76 days p.i., the percentage of apoptotic
cells returned to control values upon recovery of the cultures
(Figure 1(d) right panel; see values at p4, p6, p13, and p18).
Moreover, from this time point up to 76 days p.i. (chronic
phase), the percentage of HCV core-positive cells decreased
to 15% (Figure 1(a) right panel) vs. 80% of the acute phase,
thus mirroring viral titer trend (see Figure 1(b)). These results
strongly suggested a steady state level of HCV replication.
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Figure 1: Generation of an in vitro model of acute and chronic HCV infection. (a) Schematic representation of the strategy to obtain
long-term infected culture (LTIC). The fluorescence microscopy pictures were obtained from one representative experiment out of three
performed. Cells were labelled with anti-hepatitis C virus core 1b protein followed by Alexa Fluor 488-conjugated secondary antibody
(green); the nuclei were stained with DAPI (blue), 40× objective; (b) virus titration by qRT-PCR at different times of infection. (c) Trypan
blue dye exclusion analysis of cell viability in uninfected (CTR) and HCV-infected Huh7.5 cells at different days postinfection. Means ±
SD from three independent experiments are shown. ∗P < 0 05; ∗∗P < 0 01. (d) Biparametric flow cytometry analysis of apoptosis at
different time points after HCV infection. In the left panel, a representative dot blot of apoptosis detection is shown relative to the samples
obtained from 14 days p.i. Numbers represent the percentage of apoptotic cells either annexin V/PI double-positive (upper right
quadrant) or annexin V single-positive (low right quadrant). In the right panel, the bar graphs show the mean ± SD of the percentage of
annexin V/PI-positive cells expressed as percentage of variation vs. control uninfected cells. The mean values were obtained from four
independent experiments. ∗∗P < 0 01 vs. CTR uninfected cells.
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Collectively, the results demonstrate that initial infection
of Huh7.5 cells with low m.o.i. leads to obtain an acute
in vitro infection featured by apoptotic death of infected cells,
here named “acute phase”. This latter is followed by the
recovery of the infected cell cultures characterized by lower
virus replication and subsequently by the establishment of a
persistent infection, here named “chronic phase”. All these
characteristics indicated that an in vitro model of persistent
infection with Jc1-HCV was set up.
3.2. HCV Infection Increases ROS Production through NOX4
and NOX1 Activity. Redox changes, in particular increased
ROS levels, had been associated with HCV infection [34,
35]. Nevertheless, the impact of intracellular HCV replica-
tion on cellular redox environment is so far contradictory.
To this aim, confluent monolayers of Huh7.5 cells were
infected with HCV, and at different time points after viral
adsorption, ROS production was measured through FACS
using the ROS-sensitive probe CellROX. As shown in
Figure 2(a), a significant increase in intracellular ROS levels
(more than 3 times higher compared to control) was detected
in infected cells 8 days p.i. (p2), when HCV RNA reached the
maximum value, and was maintained at high levels during all
the apoptotic crisis period. After cell cultures recovery from
37 up to 76 days p.i., the ROS levels in infected cells returned
to control values (Figure 2(a) right panel). These results sug-
gest that intracellular ROS-mediated oxidative stress was
induced by HCV replication, and it was simultaneously
accompanied by the apoptotic phase.
Next, we investigated whether in our model the increase
of ROS levels was associated with NOXs activity, particularly
with two isoforms, NOX1 and NOX4, involved in the severity
of HCV infection [19, 36]. To this aim, Huh7.5 cells were
infected with HCV and assayed for NOX4 mRNA by
RT-PCR during the different phases of HCV infection. The
results demonstrated that the NOX4 mRNA levels doubled
6 days p.i. (p1) in infected cells with respect to uninfected
control cells; then the NOX4 mRNA levels decreased and
returned to physiological level (Figure 2(b)). Consistently,
NOX4 protein expression was upregulated in infected cells
during the acute phase, while it was decreased during the
chronic phase (Figure 2(c)). Similar results were obtained
for NOX1 enzyme, although its decrease began earlier (p3)
than NOX4.
Collectively, these data suggest NOX enzymes as one pos-
sible player in HCV-induced ROS production.
3.3. HCV Alters the GSH Redox Homeostasis. To test whether
Huh7.5 cells activated GSH antioxidant system in response
to HCV-induced oxidative stress, the intracellular content
of both reduced (GSH) and oxidized (GSSG) forms of gluta-
thione was measured at different times after HCV infection
by using a colorimetric assay. As shown in Figure 3(a), in
the early steps of acute phase of infection GSH content
diminished of about 40% (∗P < 0 05, ∗∗P < 0 01 at 2 (p0)
and 6 (p1) days p.i, respectively) compared to uninfected
cells. In contrast, the GSH levels in infected cells were signif-
icantly higher (about 70%) during cell recovery (p3) com-
pared to the control cells and were maintained at higher
levels during the chronic phase (p4, p5, and p10). More
interestingly, by comparing the acute and chronic phases,
a significant rise trend of GSH content in infected cells
was detected in the latter phases (p3, p4, and p5 vs. p0).
Conversely, as shown in Figure 3(b), the GSSG levels
increased during the acute phase, in particular the content
was doubled 8 days p.i. (p2). Interestingly, as shown in
Figure 3(c), the GSH/GSSG ratio that under physiological
conditions is maintained >1 [37] was shifted toward the
oxidized form and was <1 (p1 and p2), just when viral rep-
lication reached the peak (Figure 1(b)), while during the
chronic phase the ratio was >1, indicating a restore of phys-
iological redox environment.
Intracellular GSH is regenerated from the oxidized
form by glutathione reductase (GR) or synthesized ex novo
by the consecutive actions of glutamate cysteine ligase
(GCL) and GSH synthase (GS) [38]. Therefore, we evalu-
ated the transcriptional expression of these 3 enzymes both
during the acute and chronic phase of infection. As shown
in Figure 4(a), the mRNA levels of GR were strongly
upregulated during the early steps of infection (p1 and
p2), when the GSSG levels were high, while GCL and GS
enzyme expression increased starting from the end of acute
phase until the recovery period and when the peak of GSH
content (p3) was detected. Interestingly, these enzymes
were still activated during the chronic phase (p4), suggest-
ing the necessity to maintain a reduced environment in
long-term cultures.
Finally, we decided to evaluate whether these enzymes
were under the control of Nrf2 pathway. Therefore, we ana-
lyzed Nrf2 protein expression during both the acute and
chronic phases. As shown in Figure 4(b), Nrf2 seemed to be
downregulated by the virus in the early phases of infection,
while it was more expressed late in infection, at p4 and p10
when the chronic phase was well-established.
All these results suggest that oxidative stress during the
acute phase is useful for promoting viral replication, while
the reducing conditions observed in the chronic phase prob-
ably favor viral persistence into the cells.
3.4. Auranofin-Induced Oxidative Stress Leads to Increased
Levels of HCV RNA Copies. Since the intracellular redox
conditions seem to play a key role in the establishment of
the chronic phase of HCV infection, we decided to evaluate
whether the oxidative stress could reactivate HCV replica-
tion in chronically infected cells. For this reason, a chemical
treatment with auranofin (Au), a well-known prooxidant
drug [39] that induces ROS production in infected cells
[40, 41], was used. In our experimental model, treatment
with Au (200 nM) for 48 hrs was able to induce an incre-
ment of intracellular ROS levels by twofold, either in unin-
fected (CTR) or in HCV-infected cells (Figure 5(a)). In
parallel, the number of intracellular HCV RNA copies in
Au-treated cultures was about 40% greater than that of
untreated infected cells (Figure 5(b)). Interestingly, in this
condition, only HCV-infected cell cultures underwent apo-
ptosis (Figure 5(c)), suggesting that oxidative stress induc-
tion could favor viral replication that in turn caused cell
damage and death.
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Figure 2: HCV infection increases ROS production through the activity of NOX4. (a) Quantitative cytofluorimetric analysis of intracellular
ROS production at different time points after HCV infection in cells stained with CellROX deep red. In the left panel, data obtained from the
samples relative to 8 and 14 days p.i. are shown as one representative experiment out of three performed. Numbers represent the median
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vs. CTR uninfected cells. The dark line refers to the intracellular HCV genome copy number. (b) Real-time PCR assay of NOX4 isoform
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4. Discussion
Oxidative stress has emerged as a key contributor to the
development and progression of HCV-induced pathogenesis
of liver [34, 35, 42] and the associated development of hepa-
tocellular carcinoma [43]. The lack of an in vitro system that
recapitulates the different stages of HCV chronic infection
has hampered the disclosure of the exact mechanisms and
the mutual effect of HCV infection and oxidative stress path-
ways on the host cells. In this study, we were able to set up the
HCV infectious system in Huh7.5 cells, which are permissive
to the JFH1 infectious clone [31]. Particularly, infection of
cell monolayers with low m.o.i. of HCV allowed to obtain
first an acute infection and subsequently the establishment
of a persistent infection. We demonstrated that, during the
acute phase, high percentage of infected cells underwent apo-
ptosis and viral titer peaked, whereas during the chronic
phase viral replication was reduced and consequently the
percentage of apoptotic-infected cells. This model called
“long-term infected cultures” (LTIC) could mimic the same
stages of a natural HCV infection. It is interesting that
HCV has long been believed noncytopathic virus, and the
hepatocyte damage during infection was considered to be
mediated by the immune system. However, consistent with
previously reported results [44], we could demonstrate that
HCV induces cell death during in vitro infection of Huh7.5
cells in the absence of RIG-I-mediated innate immune
response. The presence of low number of core expressing
cells, during the here called “chronic phase”, paralleled by
the low level viral RNA titer, indicated the ability of the
JFH1 clone of HCV to persistently infect susceptible cell cul-
tures. With regard to the mechanisms involved in establish-
ing in vitro persistence, there could be a close virus-host
cell interaction, and as reported by Zhong et al. [44], in
Huh7.5 cells long-term infected by HCV, some cells resistant
to reinfection, due to the loss of HCV receptor CD81, can be
selected during the chronic phase. From the virus side, HCV
is known to exist as quasispecies in patients in vivo, and
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during persistent infection in vitro, some virus variants
can arise that are more adapted in cultures and able to
persist without killing the host cells or having reduced
infectivity [44]. These points will deserve deeper investiga-
tion in the future.
Furthermore, during HCV acute infection, a ROS over-
production, mainly mediated by NADPH-oxidase NOX4,
was registered in infected cells. NOXs are a family of seven
enzymes, generating O2
⋅− or H2O2 from molecular oxygen
[45]. Accumulating evidence indicates that NOX-mediated
ROS production has a critical role in hepatic fibrosis [46,
47], and in particular, NOX4 is involved in the severity of
HCV-associated liver disease [19, 36], as well as in the regu-
lation of viral replication of different viruses [48–50]. Here,
we found that NOX4 and NOX1 rise mirrored the trend of
ROS production and that of viral replication; in fact, their
expression was increased during the acute phase of infection,
while it decreased late in infection, thus suggesting a critical
role for NOXs also in regulating HCV replication cycle.
The reason why both NOX enzymes were downmodulated
in infected cells during the chronic phase is still unclear,
but we hypothesize that it could be a further mechanism
induced by the virus to maintain reducing environment into
host cell for the establishment of its persistence. Indeed, other
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viruses are able at the same time to positively and negatively
modulate NOX isoforms to their advantage [48–50]. Further
studies will be needed to clarify this aspect.
It is noteworthy that NOX4 is mainly localized in the
nuclei and ER and that during HCV infection the amount
of NOX4 in the nucleus increases [19], which seems to be
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one of the mechanisms underlying HCV pathogenesis.
Therefore, it is also possible to speculate that nuclear NOX4
may increase during the acute phase of HCV infection in
our experimental system, thus promoting the DNA damage
and apoptosis of infected cells. Apoptotic death might favor
virus spread throughout the cell culture. Further studies are
in progress to deepen this aspect.
It is important to note, however, that NOXs are not the
only source of ROS production in HCV-infected cells [51].
In fact, some viral proteins, i.e., core, NS3/NS4A, and
NS5A, have been shown to increase ROS levels [7, 9, 52–54]
through direct or indirect interaction with mitochondria.
Therefore, we cannot rule out that ROS increase in
HCV-infected cells might be in part produced by mitochon-
drial compartment, other than NOXs.
Because of high chemical reactivity of ROS, cells possess
antioxidant defense mechanisms for maintaining redox
homeostasis [55], whose principal component is GSH, the
main abundant intracellular antioxidant. It plays a crucial
role in sustaining redox balance, and the ratio of GSH to
GSSG is considered as a good indicator of the redox environ-
ment. To date, there is a great debate on the induction and
modulation of oxidative stress by HCV and its relationship
with acute or chronic phase of infection.
Hepatocytes are the major source of GSH in the body,
and the GSH antioxidant system plays an important role
against oxidative stress in these cells [56]. Interestingly,
reduced GSH levels were found in the serum and liver of
chronically HCV-infected patients [28, 57]. Here, we found
that intracellular GSH levels were significantly decreased in
infected cells during the acute phase, while those of GSSG
were increased, and, consequently, the ratio GSH/GSSG
shifted toward GSSG, thus reflecting an impaired antioxidant
potential. The oxidized environment seems to be necessary
for HCV to replicate as demonstrated by viral titer peak in
the acute phase. These data are in line with different
in vitro studies on viruses responsible for acute infection,
demonstrating the role of virus-induced oxidative stress in
promoting viral replication [48, 50, 58–60]. On the contrary,
during the chronic phase, reducing redox environment was
restored by increased GSH content in infected cells that
might be useful for the establishment of viral persistence.
Indeed, treatment of persistently HCV-infected cells with
the prooxidant drug auranofin caused the reactivation of
HCV replication. The mechanisms through which HCV
manipulates redox environment to its advantage are not fully
clarified yet.
It is known that GSH de novo synthesis is driven by Nrf2
(nuclear factor erythroid 2-related factor), one of the major
cellular defense mechanisms against oxidative stress and a
master regulator of different cytoprotective genes including
those involved in the antioxidant GSH pathway [61]. It has
been recently demonstrated that higher expression of nuclear
Nrf2 contributes to persistent HCV infection and that knock-
down of Nrf2 suppresses its persistent infection [62]. The
authors suggest that the nuclear translocation of p-Nrf2
might play an important role in the expression of the genes
which contribute to regulate apoptosis and HCV persistence
[25, 26, 30, 62]. Accordingly, we found higher mRNA levels
of GCL and GS enzymes during the recovery period; at the
same time, Nrf2 protein content was highly expressed dur-
ing the chronic phase. On the basis of these evidences, we
suggest that the high GSH levels registered in chronically
infected cells compared to those measured during the acute
phase of infection might be partly related to the activation of
Nrf2 pathway.
There is a great debate regarding the supplementation of
antioxidants in combination with antiviral drugs. In fact sev-
eral clinical trials reported that antioxidant therapy decreases
viral load and ameliorates hepatic damage [63]. However,
other studies reported that supplementation with vitamin
C, E, and selenium increased the antioxidant status but had
no effects on viral load or oxidative markers [64]. All these
conflicting results highlight the “dark side” of some antioxi-
dants. Therefore, on the basis of our evidences and on the lit-
erature available, we suggest to carefully consider the use of
antioxidants in chronically HCV-infected patients, since,
although they could limit liver tissue injury, they would con-
tribute to establish virus persistence that, in turn, can con-
tribute to the development of hepatocellular carcinoma.
The lack of HCV vaccine and the emergence of viral
strains resistant to antiviral therapy underline our limits in
the current weapons used to fight the infection. In the recent
years, new drugs acting specifically on HCV viral proteins
(DAA) have been developed among which are the inhibitors
of protease (telaprevir, boceprevir, and simeprevir) and the
last approved RNA polymerase inhibitor, sofosbuvir [65].
Since the emergence of drug-resistant HCV variants has
been recently described [66], there is an urgent need to iden-
tify novel targets for the design of new effective therapeutic
strategies. In this context, targeting of redox-sensitive
host-cells pathways essential for viral replication and/or per-
sistence may represent a promising option for contrasting
HCV infection.
5. Conclusions
In conclusion, we demonstrate that the acute phase of HCV
infection is characterized by a marked oxidative stress that,
similarly to other viruses, is useful for viral replication. On
the contrary, the restoration of reducing redox conditions
that characterize the chronic phase of infection might play
a key role in decreasing viral replication and apoptotic death.
Overall, our data indicate that redox sensitive pathways
control the different phases of HCV infection and suggest a
particular wariness in the supplementation of exogenous
antioxidants in chronically HCV-infected patients for their
potential role in favoring viral persistence.
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